Status:
UNKNOWN
Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Leukemia, Lymphoblastic, Acute
Eligibility:
All Genders
14+ years
Brief Summary
Philadelphia-chromosome-positive or partial ph-like acute lymphoblastic leukemia (ALL) preferred chemotherapy combined with tyrosine kinase inhibitors (TKIS) therapy. Recently we found that there were...
Eligibility Criteria
Inclusion
- Patients diagnosed with acute lymphoblastic leukemia who had not previously received chemotherapy (except for hormone preconditioning) or started with chemotherapy but not more than 3 days, and CMV and EBV quantitative negative;
- Age Limits:\>or= 14 years old.
Exclusion
- Patients who had previously received chemotherapy and hematopoietic stem cell transplantation;
- Patients with CMV and EBV infection before treatment and not to turn yin;
- The researchers considered unsuitable patients.
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03331211
Start Date
November 1 2017
End Date
September 1 2019
Last Update
November 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology,Nanfang Hospital
Guangzhou, Guangdong, China, 510515